![](/images/volltext_pdf.png)
Abstract
During an oral glucose tolerance test (OGTT) glucose and insulin levels were measured in 26 patients with prolactin-producing pituitary tumours without growth hormone excess. Basal glucose and insulin levels did not differ from the values of an age-matched control group. After glucose load the hyperprolactinaemic patients showed a decrease in glucose tolerance and a hyperinsulinaemia. Bromocriptine (CB 154), which suppressed PRL, improved glucose tolerance and decreased insulin towards normal in a second OGTT. — Human PRL or CB 154 had no significant influence on insulin release due to glucose in the perfused rat pancreas. — These findings suggest a diabetogenic effect of PRL. CB 154 might be a useful drug in improving glucose utilization in hormone-active pituitary tumours.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Keywords: | Prolactin, insulin release, glucose tolerance, pituitary tumours, pancreas perfusions, bromocriptine |
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
URN: | urn:nbn:de:bvb:19-epub-8159-8 |
ISSN: | 1432-0428 |
Sprache: | Deutsch |
Dokumenten ID: | 8159 |
Datum der Veröffentlichung auf Open Access LMU: | 05. Dez. 2008, 12:05 |
Letzte Änderungen: | 04. Nov. 2020, 12:50 |